Lulu Liane Catherine Danielle Bursztyn

Lulu Liane Catherine Danielle Bursztyn

Auto-generated profile, based on publicly available information

Lulu Liane Catherine Danielle Bursztyn

Department of Ophthalmology, Western University, London, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
SYSaerom Youn
Saerom Youn
BLBrandon Loshusan
Brandon Loshusan
JAJames J. Armstrong
James J. Armstrong
JFJ. Alexander Fraser
J. Alexander Fraser
Steffen HamannSteffen Hamann
Steffen Hamann
LBLulu L.C.D. Bursztyn
Lulu L.C.D. Bursztyn

1 October 2021 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
DSDavid Christian Schulz
David Christian Schulz
SOSamantha Miyoko Ashlyn Orr
Samantha Miyoko Ashlyn Orr
RJRochelle Johnstone
Rochelle Johnstone
MDMegan K. Devlin
Megan K. Devlin
TSThomas Gordon Sheidow
Thomas Gordon Sheidow
LBLulu Liane Catherine Danielle Bursztyn
Lulu Liane Catherine Danielle Bursztyn

18 February 2022 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
DPDaiana Roxana Pur
Daiana Roxana Pur
LBLulu Liane Catherine Danielle Bursztyn
Lulu Liane Catherine Danielle Bursztyn
YIYiannis Iordanous
Yiannis Iordanous
To report a case of a branch retinal vein occlusion (BRVO) following mRNA COVID-19 vaccination. A 34-year-old healthy male presented with blurriness in the inferior visual field, intermittent photopsia, multiple retinal hemorrhages, dilated and tortuous retinal vessels, and cotton wools spots in the right eye. The clinical examination and ancillary tests confirmed the diagnosis of a right eye BRVO. The visual symptoms started 2 days following first dose COVID-19 vaccination with the BNT162b2 (Pfizer-BioNTech) mRNA vaccine. This is a rare case of BRVO in an otherwise healthy young man, presenting after vaccination for COVID-19 in the absence of other coagulable risk factors. As the literature on venous thrombosis after COVID-19 vaccinations remains sparse, it is critical to raise awareness that BRVO could be a vaccine-related thrombotic adverse event. We highlight that as more of the population is vaccinated, an increased incidence of BRVO may confirm the link to COVID-19 vaccination.

1 December 2018 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Open access
LMLasse Malmqvist
Lasse Malmqvist
LBLulu Bursztyn
Lulu Bursztyn
FCFiona Costello
Fiona Costello
KDKathleen Digre
Kathleen Digre
JFJ. Alexander Fraser
J. Alexander Fraser
Steffen HamannSteffen Hamann
Steffen Hamann

1 April 2019 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
LBLulu L.C.D. Bursztyn
Lulu L.C.D. Bursztyn
LLLindsey B. De Lott
Lindsey B. De Lott
MPMyria Petrou
Myria Petrou
WCWayne T. Cornblath
Wayne T. Cornblath

6 January 2022 in International Journal of Retina and Vitreous
Verified
Journal Article
Open access
PDF file
NPNikhil S. Patil
Nikhil S. Patil
MIMunir M. Iqbal
Munir M. Iqbal
LBLulu L. C. D. Bursztyn
Lulu L. C. D. Bursztyn
Background: Hereditary transthyretin amyloidosis (ATTR amyloidosis) is a rare condition where a mutation in the transthyretin gene leads to systemic deposition of amyloid. The manifestations and prognosis of ATTR amyloidosis depends on the specific ATTR mutation, with over 100 mutations reported in the literature. The manifestations of many rare forms of ATTR amyloidosis have not been well described, particularly the late-onset ophthalmic findings. Case presentation: We present the case of a 43-year-old Caucasian male with a diagnosis of ATTRD18E amyloidosis confirmed by fat pad biopsy. He had diffuse systemic involvement, including cardiovascular, pulmonary, and gastrointestinal symptoms. He also had significant ocular involvement including vitreous opacities, retinal angiopathy, and conjunctival lymphangiectasia. These ocular findings modestly progressed at 2-year follow-up. Discussion: The ATTRD18E mutation is a rare variant, with few described cases. To our knowledge, this is the first documented case of ATTRD18E amyloidosis with significant ocular involvement. These ocular findings may serve as a relevant biomarker for severe disease prognosis in ATTRD18E amyloidosis. With improving treatments addressing the systemic symptoms of ATTR amyloidosis, a better understanding of the late-onset ocular symptoms is becoming increasingly relevant.